RESUMEN
OBJECTIVE: To identify, in people known to have gout, the testable, key components of a standard definition of gout flare for use in clinical research. METHODS: Consensus methodology was used to identify key elements of a gout flare. Two Delphi exercises were conducted among different groups of rheumatologists. A cognitive mapping technique among 9 gout experts with hierarchical cluster analysis provided a framework to guide the panel discussion, which identified the final set of items that should be tested empirically. RESULTS: From the Delphi exercises, 21 items were presented to the expert panel. Cluster analysis and multidimensional scaling showed that these items clustered into 5 concepts (joint inflammation, severity of symptoms, stereotypical nature, pain, and gout archetype) distributed along 2 dimensions (objective to subjective features and general features to specific features of gout). Using this analysis, expert panel discussion generated a short list of potential features: joint swelling, joint tenderness, joint warmth, severity of pain, patient global assessment, time to maximum pain, time to complete resolution of pain, an acute-phase marker, and functional impact of the episode. CONCLUSION: A short list of features has been identified and now requires validation against a patient- and physician-defined gout flare in order to determine the best combination of features.
Asunto(s)
Cognición/fisiología , Consenso , Técnica Delphi , Gota/fisiopatología , Gota/psicología , Adulto , Anciano , Análisis por Conglomerados , Recolección de Datos , Femenino , Gota/diagnóstico , Humanos , Inflamación/fisiopatología , Inflamación/psicología , Masculino , Persona de Mediana Edad , Dolor/fisiopatología , Dolor/psicología , Índice de Severidad de la EnfermedadRESUMEN
Borna disease virus (BDV) is a neurotropic pathogen that infects a wide variety of vertebrates. We have developed a new electrochemiluminescence immunoassay (ECLIA) for the detection of antibodies to BDV, using three synthetic peptides corresponding to the amino acid residues 3-20 and 338-358 of p40 and 59-79 of p24 peptide of BDV. Using the ECLIA, we examined serum samples for the presence of anti-BDV antibodies in 20 rats (experimentally BDV-infected and uninfected) and 38 horses (13 US horses, experimentally infected and uninfected, and 25 Japanese horses, feral and domestic). The ECLIA, performed in a double-blind manner, detected anti-BDV antibodies in rats with a history of BDV infection, giving results that were in agreement with indirect immunofluorescence assay and/or Western blot (WB) analysis. The ECLIA also correctly identified all three experimentally infected horses and four domestic American horses that were seropositive for BDV antibodies by WB. Among the Japanese horses, at least two out of 10 feral and six out of 15 domestic horses were seropositive for BDV. In most of these cases, the specificity of immunoreactivity was verified by blocking with soluble p40 and p24 peptides.
Asunto(s)
Anticuerpos Antivirales/sangre , Antígenos Virales/inmunología , Enfermedad de Borna/diagnóstico , Virus de la Enfermedad de Borna/inmunología , Enfermedades de los Caballos/diagnóstico , Proteínas Virales/inmunología , Secuencia de Aminoácidos , Animales , Antígenos Virales/química , Western Blotting , Enfermedad de Borna/sangre , Enfermedad de Borna/inmunología , Electroquímica/métodos , Femenino , Técnica del Anticuerpo Fluorescente Indirecta , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/virología , Caballos , Inmunoensayo/métodos , Mediciones Luminiscentes , Masculino , Datos de Secuencia Molecular , Fragmentos de Péptidos/química , Ratas , Ratas Endogámicas Lew , Ratas Wistar , Reproducibilidad de los Resultados , Proteínas Virales/químicaRESUMEN
The prevalence of Borna disease virus (BDV)-specific antibodies among patients with psychiatric disorders and healthy individuals has varied in several reports using several different serological assay methods. A reliable and specific method for anti-BDV antibodies needs to be developed to clarify the pathological significance of BDV infections in humans. We developed a new electrochemiluminescence immunoassay (ECLIA) for the antibody to BDV that uses two recombinant proteins of BDV, p40 and p24 (full length). Using this ECLIA, we examined 3,476 serum samples from humans with various diseases and 917 sera from blood donors in Japan for the presence of anti-BDV antibodies. By ECLIA, 26 (3.08%) of 845 schizophrenia patients and 9 (3.59%) of 251 patients with mood disorders were seropositive for BDV. Among 323 patients with other psychiatric diseases, 114 with neurological diseases, 75 with chronic fatigue syndrome, 85 human immunodeficiency virus-infected patients, 50 with autoimmune diseases including rheumatoid arthritis and systemic lupus erythematosis and 17 with leprosy, there was no positive case except one case each with alcohol addiction, AIDS, and dementia. Although 19 (1.36%) of 1,393 patients with various ocular diseases, 10 (1.09%) of 917 blood donors, and 3 (4.55%) of 66 multitransfused patients were seropositive for BDV-specific antigen, high levels of seroprevalence in schizophrenia patients and young patients (16 to 59 years old) with mood disorders were statistically significant. The immunoreactivity of seropositive sera could be verified for specificity by blocking with soluble p40 and/or p24 recombinant protein. Anti-p24 antibody was more frequent than p40 antibody in most cases, and in some psychotic patients antibody profiles showed only p40 antibody. Although serum positive for both p40 and p24 antibodies was not found in this study, the p40 ECLIA count in schizophrenia patients was higher than that of blood donors. Furthermore, we examined 90 sera from Japanese feral horses. Antibody profiles of control human samples are similar to that of naturally BDV-infected feral horses. We concluded that BDV infection was associated in some way with psychiatric disorders.
Asunto(s)
Anticuerpos Antivirales/análisis , Enfermedad de Borna/inmunología , Virus de la Enfermedad de Borna , Inmunoensayo/métodos , Trastornos del Humor/virología , Esquizofrenia/virología , Distribución por Edad , Animales , Animales Salvajes , Enfermedad de Borna/epidemiología , Caballos , Humanos , Mediciones Luminiscentes , Masculino , Tamizaje Masivo/métodos , Trastornos del Humor/inmunología , Proteínas Recombinantes/inmunología , Esquizofrenia/inmunología , Sensibilidad y Especificidad , Estudios Seroepidemiológicos , Distribución por SexoRESUMEN
Borna disease was originally described as an equine neurologic syndrome over 200 years ago, although the infectious etiology of the disorder was unproven until the early 20th century. Borna disease virus (BDV) was finally isolated from horses dying of the disorder, and that virus has been used to experimentally reproduce Borna disease in several species of laboratory animals. However, BDV has never been inoculated back into horses to experimentally and etiologically confirm the classic clinical, pathologic, and serologic characteristics of the disease in that species. Three ponies were intracerebrally inoculated with different amounts of BDV and were evaluated clinically, serologically, and neurohistopathologically. All 3 animals developed the clinical signs characteristically described for naturally occurring Borna disease, including ataxia, torticollis, postural unawareness, rhythmic repetitive motor activities, muscle fasciculation, and cutaneous hyperesthesia and hypoesthesia over several body surfaces. Two ponies died after rapid onset of these signs 28-30 days postinoculation. The third animal made a nearly complete clinical recovery. Seroconversion occurred only after the onset of signs and to a marked degree only in the convalescent animal. Virus was recovered postmortem from 2 of the 3 ponies, and a BDV-specific nucleic acid sequence was detectable in all 3 animals using a reverse transcription-polymerase chain reaction procedure. Gross neural lesions were absent, but histopathologically there was generalized intense mononuclear perivascular cuffing, glial nodule formation, and astrocytosis in all 3 brains. Confirming a diagnosis of Borna disease is difficult and perhaps best accomplished using a combination of the clinical, serologic, and histopathologic indicators of this unusual disease supported by positive reverse transcription-polymerase chain reaction findings.
Asunto(s)
Antígenos Virales/análisis , Enfermedad de Borna/patología , Virus de la Enfermedad de Borna/patogenicidad , Enfermedades de los Caballos/patología , Animales , Enfermedad de Borna/diagnóstico , Enfermedad de Borna/inmunología , Encéfalo/patología , Diagnóstico Diferencial , Enfermedades de los Caballos/diagnóstico , Enfermedades de los Caballos/inmunología , Caballos , Reacción en Cadena de la Polimerasa , Pruebas SerológicasRESUMEN
We detected anti-Borna disease virus (BDV) antibodies at a 14.4% rate in patients with schizophrenia. The hypothesis of a higher rate of BDV seropositivity in deficit syndrome was borne out in a subset of 64 patients categorized according to the Schedule for the Deficit Syndrome with 5/15 seropositive deficit and 4/49 seropositive nondeficit (p < 0.05). This suggests that the antibodies and possibly a BDV-like virus are pathogenetically linked to this form of schizophrenia.
Asunto(s)
Síntomas Afectivos/virología , Virus de la Enfermedad de Borna/inmunología , Trastornos del Conocimiento/virología , Esquizofrenia/virología , Adulto , Estudios de Casos y Controles , Distribución de Chi-Cuadrado , Estudios de Cohortes , Femenino , Humanos , Masculino , Esquizofrenia/clasificación , SíndromeRESUMEN
Borna disease virus (BDV) was previously believed to have a strict tropism for the nervous system. BDV has recently been identified by a reverse transcription-polymerization chain reaction-enzyme immunosorbent assay (RT-PCR-EIA) in bone marrow cells and peripheral blood mononuclear cells (PBMC) in BDV-infected Lewis rats. We now report the identification of BDV RNA and infectious virus in thymus cells from rats infected either as neonates (PTI-NB) or as adults (4 weeks of age). Based on in vitro studies, we determined that the BDV-infected cells in bone marrow and thymus tissue are fibroblastic stromal cells. Bone marrow stromal cells are nonhematopoietic, fixed-tissue elements that support hematopoiesis, and, thus, it was not surprising that BDV infection altered the recovery from granulocytopenia and leukocytopenia after myelosuppressive treatment. Notably, unlike other immunotropic and neurotropic viruses, BDV does not appear to infect cells of myeloid or lymphoid lineages. We also report the association between BDV in the thymus with the lack, or loss, of encephalitis in neonatally inoculated rats or adult-inoculated rats during the chronic stage of disease.
Asunto(s)
Médula Ósea/microbiología , Enfermedad de Borna/sangre , Virus de la Enfermedad de Borna/patogenicidad , Hematopoyesis , Timo/microbiología , Fosfatasa Alcalina/metabolismo , Animales , Ciclofosfamida/farmacología , Técnicas Inmunológicas , Masculino , Ratas , Ratas Endogámicas Lew , Timo/citología , Proteínas Virales/metabolismoRESUMEN
A formal method of evaluation is applied to a theory presented by Drs. Torrey and Yolken, which asserts that cases of viral schizophrenia are due to a zoonosis from house cats. A formal method of theory evaluation is described, and the Torrey and Yolken theory is subjected to analysis by the method. The theory is found to be weak in several areas stemming from inadequate description of both the relevant clinical population and the viral pathogenesis, as well as an incomplete examination of available data bearing on a hypothesized association between schizophrenia and cat ownership. At this point, further work is indicated at the level of theory development before proceeding with research or clinical activity.
Asunto(s)
Enfermedades de los Gatos/transmisión , Esquizofrenia/virología , Virosis/veterinaria , Zoonosis , Adolescente , Adulto , Animales , Estudios de Casos y Controles , Enfermedades de los Gatos/virología , Gatos , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Embarazo , Efectos Tardíos de la Exposición Prenatal , Factores de Riesgo , Virosis/transmisión , Virosis/virologíaRESUMEN
The development of a new serological assay method to detect antibodies in human sera recognizing Borna disease virus (BDV) proteins and a clinical pilot study are presented. Psychiatric patients from a schizophrenia research clinic in Baltimore, Maryland, were examined for antibodies to BDV antigen with traditional indirect immunofluorescence assays (IFA) that used both single and double labeling techniques and also with a Western blot assay capable of detecting antibodies to the three BDV proteins from a human neuroblastoma cell line. Thirteen of 90 (14.4%) patients and 0/20 control subjects had antibodies that recognized more than one BDV protein on the Western blot. Three patients had antibodies that recognized all three BDV proteins. Magnetic resonance imaging assessments of the volume of the putamen (with controls for total cranial volume) differentiated BDV+ from BDV- patients, and there were trend differences for bilateral amygdalae and the left amygdala-hippocampal process. We conclude that: (1) the Western blot assay is superior to IFA assays in BDV serology studies, (2) detection of antibodies to more than one BDV protein is a useful working criterion for seropositivity, (3) the 14.5 kDa BDV protein is 10 times more predictive of seropositivity than either the 38/40 kDa or the 24 kDa protein, (4) there is tentative evidence for a schizophrenia-control difference in the prevalence of anti-BDV antibodies, and (5) it is likely that there are neuroanatomical/behavioral features that differentiate seropositive from seronegative schizophrenic patients.
Asunto(s)
Anticuerpos Antivirales/sangre , Virus de la Enfermedad de Borna/inmunología , Trastornos Neurocognitivos/inmunología , Esquizofrenia/inmunología , Psicología del Esquizofrénico , Adulto , Atención Ambulatoria , Western Blotting , Encéfalo/patología , Diagnóstico Diferencial , Femenino , Técnica del Anticuerpo Fluorescente , Humanos , Imagen por Resonancia Magnética , Masculino , Maryland , Persona de Mediana Edad , Trastornos Neurocognitivos/diagnóstico , Trastornos Neurocognitivos/psicología , Pruebas Neuropsicológicas , Escalas de Valoración Psiquiátrica , Valores de Referencia , Esquizofrenia/diagnósticoRESUMEN
Clozapine is an atypical neuroleptic medication with superior efficacy to conventional antipsychotic agents for patients with chronic, symptomatic schizophrenia. Neurochemical characteristics that distinguish clozapine from other neuroleptics and contribute to its differential efficacy are not known. We assessed the effects of clozapine on plasma levels of norepinephrine (NE) in a double-blind, parallel groups comparison of clozapine (n = 11) and haloperidol (n = 15) in chronic schizophrenic outpatients who had been previously treated with fluphenazine. Simultaneous measurements were obtained for plasma levels of the catecholamine precursor dopa, the dopamine metabolite dihydroxyphenylacetic acid (DOPAC), the NE metabolite 3,4-dihydroxyphenylglycol (DHPG), adrenocorticotropin (ACTH), cortisol, and hemodynamic parameters. Clozapine produced marked increases (471%) in plasma NE levels, whereas haloperidol had no significant effects on plasma NE levels. Clozapine also increased dopa and tended to increase DOPAC levels, without effects on DHPG, ACTH, or cortisol levels and without consistent changes in blood pressure. Across patients, the magnitude of clozapine-induced increments in plasma NE levels was positively related to improvement in positive symptoms and global symptomatology and was unrelated to the occurrence of extrapyramidal symptoms. The results suggest that clozapine differs importantly from other neuroleptics in increasing plasma NE levels, with the peripheral noradrenergic stimulation related to its superior efficacy profile. The unchanged DHPG levels and absence of hypertension suggest a more complex mechanism of action of clozapine than heightened NE release alone.
Asunto(s)
Clozapina/farmacología , Norepinefrina/sangre , Ácido 3,4-Dihidroxifenilacético/sangre , Hormona Adrenocorticotrópica/sangre , Adulto , Análisis de Varianza , Clozapina/uso terapéutico , Dihidroxifenilalanina/sangre , Método Doble Ciego , Femenino , Haloperidol/farmacología , Haloperidol/uso terapéutico , Hemodinámica/efectos de los fármacos , Humanos , Hidrocortisona/sangre , Masculino , Naftoles/sangre , Glicoles de Propileno/sangre , Escalas de Valoración Psiquiátrica , Esquizofrenia/tratamiento farmacológico , Psicología del EsquizofrénicoRESUMEN
We developed a mouse model of Borna disease to facilitate immunopathogenesis research by adaptation of Borna disease virus to mice through serial passage in mouse brain tissue. Borna disease virus replication, antibody production, inflammation, and Borna disease expression in several different strains of mice were examined.
Asunto(s)
Enfermedad de Borna/microbiología , Modelos Animales de Enfermedad , Animales , Anticuerpos Antivirales/sangre , Enfermedad de Borna/patología , Virus de la Enfermedad de Borna/crecimiento & desarrollo , Encéfalo/microbiología , Encefalitis/patología , Variación Genética , Ratones , Ratones Endogámicos , Actividad Motora , Pase SeriadoRESUMEN
Borna disease virus (BDV) is a negative-strand RNA virus which produces persistent infection in a variety of experimental animals. In the rat, the presence or absence of clinical signs of Borna disease, a characteristic, biphasic neurobehavioral illness, depends on host-related factors. A window of opportunity exists after birth wherein inoculation with BDV produces a persistently infected rat without signs of Borna disease or encephalitis (persistent, tolerant infection-newborn [PTI-NB] rat). Although immunopathological destruction of the nervous system does not occur in the PTI-NB rat, significant alterations in the development of the nervous system were noted, including site-specific lysis of neurons. Unlike the case with other pharmacologically produced, persistent, tolerant BDV infections, adoptive transfer of spleen cells from BDV-infected rats did not produce disease in the PTI-NB rats. PTI-NB rats developed Borna disease after being connected by parabiosis to rats with Borna disease. Bone marrow transplantation experiments revealed that bone marrow cells from PTI-NB rats produced Borna disease in lethally irradiated, BDV-infected recipient rats. Bone marrow from PTI-NB rats contained a complement of inflammatory cells capable of inducing Borna disease. Thus, the loss of BDV-specific cellular immunity appeared to occur after the release of cells from the bone marrow.
Asunto(s)
Enfermedad de Borna/inmunología , Virus de la Enfermedad de Borna/inmunología , Encéfalo/microbiología , Animales , Animales Recién Nacidos , Antígenos Virales/análisis , Trasplante de Médula Ósea/inmunología , Enfermedad de Borna/microbiología , Enfermedad de Borna/patología , Encéfalo/inmunología , Encéfalo/patología , Cerebelo/inmunología , Cerebelo/microbiología , Cerebelo/patología , Antígenos de Histocompatibilidad Clase I/análisis , Antígenos de Histocompatibilidad Clase II/análisis , Inmunoterapia Adoptiva , Células de Purkinje/inmunología , Células de Purkinje/microbiología , Células de Purkinje/patología , Ratas , Ratas Endogámicas Lew , Nervio Ciático/inmunología , Nervio Ciático/microbiología , Nervio Ciático/patología , Bazo/inmunologíaAsunto(s)
Trastorno Depresivo/etiología , Trastornos Psicóticos/psicología , Enfermedad Aguda , Trastorno Depresivo/diagnóstico , Trastorno Depresivo/psicología , Humanos , Escalas de Valoración Psiquiátrica , Trastornos Psicóticos/complicaciones , Proyectos de Investigación/normas , Esquizofrenia/complicaciones , Psicología del Esquizofrénico , Terminología como AsuntoRESUMEN
A double-blind crossover trial was used to evaluate carbamazepine as the sole maintenance treatment of chronic, nonmanic schizophrenic outpatients whose conditions had been stabilized with the use of neuroleptics prior to study. Criteria of treatment effectiveness included the number of patients relapsing and time to relapse over a 95-day neuroleptic-free period during which either carbamazepine or placebo was administered. Relapse was determined by the concordance of psychiatric ratings and independent clinical judgements indicating significant worsening. Results for 27 patients (13 receiving carbamazepine and 14 receiving placebo) involved in the first phase of this treatment comparison were nondifferentiating. Corroborating descriptive findings in the second phase were available for 14 of these patients. There was no evidence supporting the existence of a treatment-relevant subgroup defined by episodic dyscontrol phenomena.
Asunto(s)
Atención Ambulatoria , Carbamazepina/uso terapéutico , Esquizofrenia/prevención & control , Adulto , Antipsicóticos/uso terapéutico , Carbamazepina/administración & dosificación , Carbamazepina/sangre , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Placebos , Recurrencia , Esquizofrenia/diagnóstico , Esquizofrenia/tratamiento farmacológico , Psicología del EsquizofrénicoRESUMEN
A theory is proposed that explains a broad range of clinical manifestations in schizophrenia. It is a heuristic device for organizing research in the neuroimmunology and virology of schizophrenia. This approach is different from other immune and viral theories of schizophrenia and defines testable hypotheses for further theory refinement or rejection. Defective alpha-interferon (aIFN) regulation resulting in excessive effect is postulated to cause schizophrenia. The role of aIFN in the regulation of development and its induction within the brain by the reactivation of viruses that are commonly present in the normal central nervous system (CNS) are the primary pathophysiological mechanisms. Biological properties of aIFN include neural excitation, opiate and adrenocorticotropic hormone activity, and inhibition of cellular proliferation and differentiation. Psychosis results from in situ viral stimulation of aIFN production in the CNS of a vulnerable host having defective regulation of either sensitivity or production. Negative symptoms result from aIFN effects on CNS development and the behavioral toxicity of aIFN. Biological developmental abnormalities, gender differences in severity, and decline in psychotic symptoms with age are discussed in the context of the theory. Research strategies and specific testable hypotheses are presented.
Asunto(s)
Encefalopatías/complicaciones , Interferón Tipo I/fisiología , Neuroinmunomodulación , Esquizofrenia/fisiopatología , Virosis/complicaciones , Adulto , Factores de Edad , Encéfalo/crecimiento & desarrollo , Encéfalo/inmunología , Encéfalo/microbiología , Encefalopatías/inmunología , Encefalopatías/fisiopatología , Femenino , Humanos , Interferón Tipo I/biosíntesis , Interferón Tipo I/inmunología , Masculino , Persona de Mediana Edad , Modelos Biológicos , Modelos Neurológicos , Esquizofrenia/diagnóstico , Esquizofrenia/etiología , Psicología del Esquizofrénico , Factores Sexuales , Activación Viral , Virosis/inmunología , Virosis/fisiopatología , Virus/crecimiento & desarrollo , Virus/inmunologíaRESUMEN
Semistructured interviews with 28 schizophrenic patients were videotaped. The affective flattening section of the Scale for the Assessment of Negative Symptoms (SANS) was rated after each interview. At a later date, each videotape was rated by three raters as well as the interviewer. Reliability was estimated within and across rating conditions by intraclass correlation. Comparison of reliability scores across rating conditions indicated that the videotape medium had little effect on the ability of raters to rate affective flattening similarly.
Asunto(s)
Entrevista Psicológica , Trastornos del Humor/psicología , Esquizofrenia/diagnóstico , Psicología del Esquizofrénico , Grabación de Cinta de Video , Humanos , Trastornos del Humor/diagnóstico , Escalas de Valoración PsiquiátricaRESUMEN
In an open trial, nine drug-free schizophrenic patients received oral diazepam, 10 to 40 mg/day, for the treatment of early symptoms of relapse. Diazepam treatment led to a return of the patient's usual condition in seven of 11 episodes.